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ABSTRACT
There is worldwide concern about the appearance and rise of bacterial resistance to commonly used
antibiotics. Although the gut is an important reservoir for resistant Escherichia coli, data from large-scale
epidemiological studies concerning the colonisation dynamics of the normal gut flora with resistant
E. coli during and after antibiotic therapy are sparse. Accordingly, a large community-based study was
conducted to ascertain changes in the prevalence of resistant E. coli during and after antibiotic treatment.
Stool samples before, during and after antibiotic therapy were obtained from 541 patients (aged
‡40 years) with a febrile infection who attended a general practitioner in southern Germany. The MICs
of commonly prescribed antibiotics for E. coli isolates from the stools were determined. The prevalence
of resistance to the corresponding antibiotics rose from 18% to 38%, from 29% to 58% and from 33% to
67% during treatment with b-lactam antibiotics, doxycycline and co-trimoxazole, respectively.
Prevalences of resistance in the E. coli isolates also rose for other antibiotic classes. With the exception
of co-trimoxazole resistance, prevalences of resistance returned to baseline levels in <2 weeks after the
cessation of antibiotic therapy. Thus, there was a substantial, but rapidly reversible, increase in the
prevalence of resistant E. coli isolates during antibiotic treatment.
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INTRODUCTION
There is worldwide concern about the appearance
and rise of bacterial resistance to commonly used
antibiotics [1,2]. Widespread use of antibiotics is
thought to be the main reason for this increase.
Current antibiotic intake is assumed to suppress
susceptible flora and lead to an overgrowth of
(pre-existing) resistant strains [3]. During this
period, potential resistant pathogens may spread
within the body, or to other individuals, and
cause serious infections. The risk of transfer of
resistance genes also increases during the over-
growth of resistant bacteria [4]. It is therefore
important to know whether, and when, the
microflora returns to normal.
To the best of our knowledge, no previous large-
scale population-based study has assessed tempo-
ral changes in the predominance of resistant and
susceptible bacterial strains in the gut. Accord-
ingly, a community-based study was conducted to
investigate the colonisation dynamics of the nor-
mal gut flora with resistant Escherichia coli during
and after antibiotic therapy. As infections with
resistant E. coli can lead to life-threatening situa-
tions, especially among the elderly, the study pop-
ulation was restricted to patients aged ‡40 years.
MATERIALS AND METHODS
Study population and data collection
Between September 2003 and September 2004, patients aged
‡40 years with acute febrile infection who had attended one of
19 general practitioners (GPs) collaborating in the study in
Ulm, a city in southern Germany, were recruited. Additional
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inclusion criteria were: patient known to the GP for at least
1 year; adequate knowledge of the German language; and
absence of severe impairment because of chronic somatic or
mental disease. In total, 541 patients were willing to participate
in the study and gave informed consent.
Data concerning known or suspected potential determi-
nants of antibiotic resistance, as well as socio-demographical
variables, e.g., age, gender, nationality and marital status,
were obtained from the patients by means of a comprehensive
self-completed standardised questionnaire. Each patient’s
current diagnosis and (where applicable) antibiotic prescrip-
tion were reported by the GP, and further medical informa-
tion, e.g., co-morbidity, was retrieved from each patient’s
chart. Each patient also recorded antibiotic intake on a
calendar covering a time window of up to 14 days after
recruitment (antibiotic treatment lasted £10 days for 95% of
the patients). Regardless of the therapy prescribed, all partic-
ipants were asked to collect a stool sample on the day of the
practice visit (t0), and after a further 7 days (t1) and 14 days
(t2), and to document the exact dates of the collection. The
samples could be obtained at home and were mailed to the
study laboratory at the Department of Medical Microbiology
and Hygiene at the University of Ulm. The study was
approved by the Ethical Committees of the Medical Faculty
of the University of Heidelberg and the Chamber of Physicians
of the Federal State of Baden-Wu¨rttemberg.
Culture of E. coli and antibiotic susceptibility tests
Stool samples were incubated on MacConkey plates at
36 ± 1C for 24 h. Colonies of different phenotypic appearance
were tested with the API 20E system (bioMe´rieux, Marcy
l’Etoile, France) to identify E. coli strains. Up to three pheno-
typically different and arbitrarily selected E. coli colonies were
kept frozen at )80C in microbanks until susceptibility testing
was performed. In the case of phenotypically different E. coli
colonies, only one randomly chosen colony was used for
susceptibility testing. MICs were determined using the Micro-
naut-SB system. (Merlin Diagnostika GmbH, Bornheim-Hersel,
Germany) according to the manufacturer’s recommendations.
Susceptibility testing is based on the rehydration of several
antibiotics in microwell plates, and is then interpreted using an
optical reader (Merlin Diagnostika) according to German
national standards (DIN 58940) [5]. The range of antibiotic
concentrations used was: ampicillin, 1–128 mg ⁄L; amoxycil-
lin–clavulanic acid, 1 ⁄ 2–128 ⁄ 2 mg ⁄L; piperacillin–tazobactam,
1 ⁄ 4–128 ⁄ 4 mg ⁄L; cefuroxime, 1–128 mg ⁄L; cefpodoxime–
proxetil, 0.25–32 mg ⁄L; cefotaxime, 0.25–32 mg ⁄L; merope-
nem, 0.25–32 mg ⁄L; nalidixic acid, 1–128 mg ⁄L; levofloxacin,
0.0625–8 mg ⁄L; gentamicin, 0.25–32 mg ⁄L; doxycycline,
0.25–32 mg ⁄L; and co-trimoxazole, 2–128 mg ⁄L. E. coli strain
ATCC 25922 was used for weekly quality control tests. MICs
were determined (breakpoints in mg ⁄L) for: ampicillin (>8),
amoxycillin–clavulanic acid (>8 ⁄ 2), piperacillin–tazobactam
(>32 ⁄ 4), cefpodoxime proxetil (>4), cefuroxime (>8), doxycy-
cline (>4), gentamicin (>4), co-trimoxazole (>64), levofloxacin
(>2) and nalidixic acid (>2).
Statistical analyses
Descriptive statistics were used to characterise the study
population with respect to various socio-demographical and
medical factors. E. coli resistance prevalences were calculated
separately at t0, t1 and t2 for patients without antibiotic
treatment and for patients receiving b-lactam antibiotics,
doxycycline, co-trimoxazole or a fluoroquinolone, respectively.
Patients who had stopped taking an antibiotic <1 week before
t0, or who were still taking an antibiotic at t2, were excluded.
Only patients who were colonised with sensitive E. coli
isolates at baseline (t0) were included in longitudinal analyses.
The longitudinal changes in the proportions of ampicillin,
co-trimoxazole, doxycycline and levofloxacin-resistant and
-sensitive isolates were analysed. For this analysis, the partic-
ipants were classified in the following categories: ‘patients
without antibiotic intake (after t0)’; ‘patients with an intake of
the antibiotic class corresponding to each specific resistance
(homologous resistance)’; and ‘patients with an intake of
another antibiotic class’.
Further analyses regarding the impact of antibiotic intake
and the temporal relationship with the development and
persistence of antibiotic resistance were restricted to ampicil-
lin, doxycycline and co-trimoxazole because the prevalences of
resistance to other agents were too low to perform meaningful
analyses of association. For these analyses, the temporal
allocation of the stool samples to the respective sampling
day (t0, t1 and t2) could no longer be used, because the
initiation and the duration of antibiotic therapy was heteroge-
neous among the patients. For example, some participants had
already completed antibiotic therapy at t1, while others were
still taking antibiotics. Each sample was therefore classified in
defined intervals after initiation and cessation of the antibiotic
therapy. Thus, to estimate the dependence of colonisation with
resistant E. coli on the time since the beginning of antibiotic
treatment, the samples were categorised into ‘no antibiotic
intake or antibiotic intake not yet started’, and therapy started
‘today’, ‘1 day ago’, ‘2–7 days ago’ and ‘8–14 days ago’. Stool
samples that were obtained after the end of the therapy, or
samples from patients who had stopped previous antibiotic
intake <1 week before t0, were not included in this analysis.
The dependence of the persistence of colonisation with
resistant E. coli on the time interval since the last antibiotic
intake was estimated in a separate analysis. All samples were
classified in the following categories: ‘current antibiotic intake
(for at least 4 days) or last antibiotic intake 1 day ago’; and last
antibiotic intake ‘2–5 days ago’, ‘6–9 days ago’, ‘10–14 days
ago’, ‘15–30 days ago’, or ‘>1 month ago’. The first four groups
only included participants who had an antibiotic prescription
at baseline, and the last two groups only included subjects who
had not received an antibiotic during their visit to the GP or in
the 2 weeks before the stool sample was collected.
In both analyses of association, multiple stool samples per
participant were included where applicable, and intra-indi-
vidual dependence of observations was taken into account by
using a generalised linear equations approach. All analyses
were carried out using the SAS statistical software package
v.8.2 (SAS Institute, Inc., Cary, NC, USA).
RESULTS
In total, 541 patients with an acute febrile infec-
tion were recruited during a visit to one of the
GPs collaborating in the study. All 541 partici-
pants submitted a stool sample at t0 and t1, and
534 patients (98.7%) submitted a third stool
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sample at t2. E. coli was cultured from 343 (63.4%)
of the first set of samples, from 275 (50.8%) of the
second set of samples, and from 307 (57.5%) of
the third set of samples.
Socio-demographical and medical characteris-
tics of the study population are summarised in
Table 1. The mean age (±SD) of the participants
was 57.5 (±12) years. In total, 287 (53.0%) patients
were prescribed an antibiotic. Fig. 1 presents the
prevalence of resistance of the E. coli isolates to
various antibiotics at t0, t1 and t2. Only minor
variations in resistance were observed for patients
without antibiotic intake (Fig. 1a), with 24.9%,
19.7% and 7.5% of the E. coli isolates being
resistant at baseline to ampicillin, doxycycline
and co-trimoxazole, respectively, and 1–2% being
resistant to cephalosporins, gentamicin or levo-
floxacin.
Resistance among isolates from patients who
received a b-lactam antibiotic prescription at their
practice visit (Fig. 1b) was considerably higher
during antibiotic therapy (at t1), with an increase
in resistance to 38%, 7%, 31% and 10% for
Table 1. Demographical and medical characteristics of the
study participants
Characteristics n %
Age
40–50 years 169 32.0
51–60 years 137 26.0
61–70 years 116 22.0
‡71 years 106 20.0
Gender
Male 181 33.6
Last antibiotic therapy at baseline (t0)
>12 months ago 346 66.3
Within the previous12 months 145 27.8
Within the previous week 31 5.9
Hospital stay within the previous 12 months 76 14.0
Most common diagnoses on the day of practice visit (more than one diagnosis
possible)
Bronchitis 210 38.8
Laryngitis ⁄pharyngitis 167 30.9
Sinusitis 127 23.5
Febrile infection 105 19.4
Urinary tract infection 69 12.8
Most common antibiotics prescribed at practice visit (n = 287)
Macrolides 90 31.4
Fluoroquinolones 65 22.7
Tetracyclines 59 20.6
Co-trimoxazole 34 11.9
b-Lactam antibiotics 39 13.6
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Fig. 1. Prevalence of resistance among Escherichia coli
isolates on the day of practice visit (t0), after a further
7 days (t1), and after 14 days (t2) for patients (a) without
antibiotic therapy, (b) receiving b-lactam antibiotics, (c)
receiving doxycycline, (d) receiving co-trimoxazole, and (e)
receiving a fluoroquinolone. AMP, ampicillin; AMC,
co-amoxyclav; TZP, piperacillin–tazobactam; CPD, cefpo-
doxime; CXM, cefuroxime; DOX, doxycycline; GEN, gen-
tamicin; SXT, co-trimoxazole; NAL, nalidixic acid, LVX,
levofloxacin.
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ampicillin, cefuroxime, doxycyline and nalidixic
acid, respectively. After ceasing antibiotic intake
(t2), resistance levels were close to those at
baseline (t0).
Fig. 1c shows the resistance levels among the
isolates from patients during and after treatment
with doxycycline. Resistance to ampicillin and
doxycycline at t0 was relatively high at 31% and
29%, respectively, and increased during treat-
ment to 42% and 58%, respectively. Resistance to
co-trimoxazole also increased during treatment.
Similarly, there was a considerable increase in
resistance to ampicillin, doxycycline, gentamicin,
co-trimoxazole and quinolones during treatment
with co-trimoxazole (Fig. 1d). Thus, resistance
rose from 29% to 56% for ampicillin, from 29%
to 50% for doxycycline, and from 33% to 67% for
co-trimoxazole. After the cessation of antibiotic
therapy, the levels of resistance rapidly
decreased. Resistance to ampicillin and quinol-
ones also increased during treatment with a
quinolone (Fig. 1e), with resistance to nalidixic
acid and levofloxacin reaching 22% at t1.
Table 2 summarises the longitudinal changes in
ampicillin, doxycycline, co-trimoxazole and levo-
floxacin-resistant and -sensitive E. coli during the
study period. Only patients with E. coli isolates
sensitive at t0 to the specific antibiotic being tested
were used in the analyses. Seven days after the
practice visit (t1), homologous resistance to ampi-
cillin, doxycycline and co-trimoxazole was notice-
ably increased in comparison with the group of
patients with no intake of antibiotic, and also in
comparison with the participants who received
other classes of antibiotics. Two weeks after
baseline (typically c. 1 week after cessation of
antibiotic therapy), homologous resistance levels
declined, but were still higher than those at
baseline for doxycycline and co-trimoxazole.
Table 3 summarises the relationship between
isolation of ampicillin, doxycycline and co-trim-
oxazole-resistant E. coli and the time of initiation
of antibiotic therapy. When antibiotic therapy was
started, resistance levels were similar to those
before treatment. After 1 day of therapy, only co-
trimoxazole resistance levels were significantly
increased, but ampicillin, doxycycline and
co-trimoxazole resistance levels were all signifi-
cantly increased after therapy for 2–7 days
(OR 3.5, 95% CI 1.3–9.1; OR 5.0, 95% CI 1.9–
13.1; and OR 7.8, 95% CI 2.5–24.1, respectively).
Even higher resistance levels were detected after
treatment with ampicillin or co-trimoxazole for
‡8 days. Four (67%) of six patients with antibiotic
therapy were colonised with ampicillin- and co-
trimoxazole-resistant E. coli, as compared to
22.3% and 8.2%, respectively, of patients who
were not receiving antibiotics.
Table 2. Carriage of ampicillin,
doxycycline, co-trimoxazole and lev-
ofloxacin-resistant Escherichia coli at
7 days (t1) and 14 days (t2) by
patients with sensitive E. coli iso-
lates on the day of the initial practice
visit (t0)
Cultured
at t1
Resistant
at t1 (%)
Cultured
at t2
Resistant
at t2 (%)
Patients with ampicillin-sensitive
E. coli at t0 (n = 285) 158 174
Without antibiotic intake 106 9 (8.5) 99 6 (6.1)
Following intake of b-lactam
antibiotics
15 5 (33.3) 15 1 (6.7)
Following intake of antibiotics
of other classes
37 5 (3.5) 60 6 (10.0)
Patients with doxycycline-sensitive
E. coli at t0 (n = 271) 165 178
Without antibiotic intake 111 5 (4.5) 105 6 (5.7)
Following intake of
tetracycline
17 5 (29.4) 16 3 (18.8)
Following intake of
antibiotics of other classes
37 7 (18.9) 57 4 (7.0)
Patients with co-trimoxazole-sensitive
E. coli at t0 (n = 303) 188 200
Without antibiotic intake 132 2 (1.5) 123 4 (3.3)
Following intake of
co-trimoxazole
8 4 (50.0) 11 3 (27.3)
Following intake of
antibiotics of other classes
48 3 (6.3) 66 8 (11.9)
Patients with levofloxacin-sensitive
E. coli at t0 (n = 338) 214 239
Without antibiotic intake 142 0 134 0
Following intake of
fluoroquinolones
1 0 13 1 (7.7)
Following intake of
antibiotics of other classes
71 0 82 0
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Resistance levels according to the interval
since the last antibiotic intake are shown in
Table 4. Ampicillin, doxycycline and co-trimox-
azole resistance levels were moderately, but not
significantly, decreased among patients who had
ceased taking antibiotic therapy 2–9 days previ-
ously, compared with those who were still
taking antibiotics. After at least 10 days follow-
ing cessation of antibiotic therapy, colonisation
with doxycycline-resistant E. coli was signifi-
cantly reduced, with only 20% of the patients
having resistant E. coli, compared with 49% of
patients who were currently taking antibiotics.
Colonisation with ampicillin- and co-trimoxaz-
ole-resistant bacteria after 10–14 days was also
considerably lower than among patients with
current antibiotic intake, but these results were
not significant because of the small number of
patients in these subgroups. Patients with no
antibiotic treatment within the last 2 weeks, but
with an intake within the last month, yielded
isolates with significantly reduced ampicillin,
doxycycline and co-trimoxazole resistance levels
as compared with patients who were currently
taking antibiotics (Table 4). The results obtained
for the group with no antibiotic intake within the
last month supported the finding that current
antibiotic intake is a major risk-factor for coloni-
sation with resistant E. coli.
DISCUSSION
This large population-based study investigated
the dynamics of antibiotic resistance levels
among E. coli isolates during and after antibiotic
therapy. Current antibiotic intake increased the
levels of resistance significantly and rapidly.
Increased colonisation with resistant E. coli was
found soon after the start of antibiotic therapy,
and intake for ‡2 days was associated with a
significantly elevated risk of carrying ampicillin-,
doxycycline- and co-trimoxazole-resistant E. coli,
even following treatment with antibiotic classes
other than those being analysed. With the excep-
tion of co-trimoxazole, resistance levels returned
to baseline c. 2 weeks after the cessation of
antibiotic therapy.
In 2000, Edlund and Nord [3] reviewed the
effect of oral antibiotics for the treatment of
urinary tract infections on the normal human
microflora [3]. Few of the studies reviewed
includedmore than ten participants. Nevertheless,T
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overgrowth with resistant enterobacteria has been
observed during therapy with b-lactam antibiotics
(ampicillin, amoxycillin and co-amoxyclav) [6–9],
although no development of resistance was seen
during cephalosporin therapy, except in associa-
tion with cefaclor treatment in one study [6].
Similarly, levofloxacin therapy did not result in an
increase in the level of resistant bacteria [10].
However, these previous studies did not provide
statistical analyses concerning the effects of the
antibiotic therapy, mostly because of the small
numbers of patients included in the studies and
the absence of control groups.
Stu¨rmer et al. [11] investigated the effect of
antibiotic therapy on colonisation with antibiotic-
resistant E. coli in the gut of outpatients. Current
antibiotic use was associated strongly with faecal
colonisation by antibiotic-resistant E. coli, but the
small number of participants with antibiotic
intake precluded an analysis of individual antibi-
otics. A study from Spain investigated changes in
the quinolone resistance of E. coli in the faeces of
patients with prostatitis who were treated with
high-dose oral ciprofloxacin [12]. In 11 of 23
patients from whom only quinolone-susceptible
E. coli was isolated before treatment, quinolone-
resistant strains predominated during and after
the course of therapy. However, 2 months after
treatment, the resistant strains had been com-
pletely displaced by quinolone-susceptible E. coli.
Similarly, a longitudinal study from The Nether-
lands analysed stool samples of 189 outpatients
with respiratory tract infection before and just
after completing antibiotic treatment [13]. Amoxy-
cillin therapy significantly increased the post-
treatment level of resistance to amoxycillin and
doxycycline among Enterobactericeae, and the
level of amoxycillin resistance among E. coli
isolates also increased significantly in patients
who had received antibiotic treatment of any kind.
There were only minor differences in the doxycy-
cline and co-trimoxazole resistance levels among
E. coli isolates pre- and post-antibiotic treatment.
The results of the present study support the
hypothesis that sensitive strains are eliminated
under the pressure of antibiotic therapy, and that
pre-existing resistant strains become more impor-
tant. The quickly emerging and reversible effect of
antibiotic therapy with respect to antibiotic resis-
tance can best be explained by the widespread
existence, but relative paucity, of resistant strains.
The observation that the intake of specific agentsT
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also promotes resistance to other antibiotic classes
is most likely caused by a survival advantage
resulting from the selection of E. coli strains with
multiple resistance traits, which may have been
acquired either by mutation of existing genes or
by acquisition of heterologous resistance genes
from external sources [14].
Several limitations should be kept inmind in the
interpretation of this study. First, although no
informationwas available concerningpatientswho
declined to participate in the study, colonisation
with E. coli was not as high as expected. The low
colonisation rate could be explained by adecreased
number of E. coli organisms in the gut following
recent or current antibiotic therapy at t1 and t2,
particularly for patients who received fluoro-
quinolone therapy, but individuals with doxycy-
cline and co-trimoxazole intake also showed
significantly less colonisation with E. coli. For
logistical reasons, only one of up to three
phenotypically different E. coli colonies could be
included in further analyses, but as selection was
random,no systematic error shouldbias the results.
Second, because of the variable length of
antibiotic therapy, not all patients were still
taking an antibiotic at t1, and the time since the
cessation of antibiotic therapy at t2 varied in the
longitudinal analyses shown in Fig. 1. Additional
analyses were therefore performed to investigate
resistance levels at defined time intervals after
initiation and cessation of antibiotic treatment.
The data from multivariate analyses are not
shown, because the adjustment for other risk-
factors, e.g., age, hospitalisation within the pre-
vious year, contact with nursing home residents
or meat consumption, did not affect the results.
This finding was not unexpected, as these deter-
minants did not change among the individual
participants during the 2-week study period.
In conclusion, antibiotic therapy often results in
the overgrowth of resistant strains. During and
after therapy, when resistant strains are dominant
in the microflora, the risk of self-infection or
spread of resistance is elevated. Two weeks after
therapy, when the sensitive flora has again
become predominant over the resistant strains, it
is probable that resistant strains are still present,
albeit in the minority. Thus, the threat of infection
or transmission does not vanish, but decreases
shortly after the cessation of antibiotic treatment.
Austin et al. [15] demonstrated the association
between levels of antimicrobial consumption in
human communities and the frequency of resis-
tance. Therefore, even if the individual risk of
carrying resistant E. coli decreases shortly after
the cessation of antibiotic treatment, the intake of
antibiotics most likely adds to the overall burden
of antibiotic resistance in the population.
Finally, after treatment failure, antibiotics
should, whenever possible, be prescribed only
according to the results of susceptibility testing,
taking into account not only the increase in
homologous resistance, but also the possible
increase in heterologous resistance to different
antibiotic classes that occurs during a course of
antibiotic treatment.
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